How is the Quick to Care™ program made to fit your journey?

Streamlining the supply chain and accelerating development

It is estimated that on average, the cost to bring a new medicine through development into commercial is $985 million.1 Available data is based on smaller new and emerging companies between 2009–2018, with products in certain therapeutic areas. These include priority review, breakthrough therapy, fast track and orphan drugs, creating the need for an expedited approval process.2

A single vendor solution that streamlines the supply chain and accelerates the development timeline is critical in ensuring that these new medicines are brought to market on time. Coordinating multiple vendors requires additional time, resources, and expertise to manage the various projects and timelines associated with drug development. This often leads to delays in development and miscommunication between vendors.

The Quick to Care™ program, offers an end-to-end, integrated, and customizable solution. Quick to Care global experts integrate drug development and clinical services into a single vendor solution. The program streamlines and accelerates your discovery and covers all development phases, by combining drug substance and drug product development, clinical trials supply solutions including packaging, labeling, storage and distribution, regulatory services, transportation management, commercial manufacturing and packaging.

Integrated drug development and clinical services

Whether you work with us on drug product and clinical trial manufacturing or all the way from drug substance to clinical supply optimization, our subject matter experts bring deep experience in their specialties and operate as a connected, accessible team to solve your challenges faster. We combine proven end-to-end capabilities and state of the art technology with dedicated program managers who treat your drug as if it’s their own. We employ an expert global network to work to reduce your timeline and get you to clinic sooner and are committed to simplifying and accelerating the development process.

Accelerating development timelines

The Quick to Care program, has allowed our clients to develop their small molecule candidates an average of 8–12 weeks faster, and large molecules an average of 14–20 weeks faster than the industry standard. Our clients have reduced their drug development timelines by an average of 14 weeks, which translates to a total net gain of approximately $44 million, as reported by the Tufts Center for the Study of Drug Development

Dedicated project management

The Quick to Care program begins with a dedicated program manager who is assigned to your program before the contract is signed. The program manager is the integrator that pulls together our broad, industry-leading capabilities into a single, integrated solution. They are responsible for reaching across our extensive network to pull together a team of technical experts to focus on your program. Your program manager is your single point of contact, who establishes and manages the governance process.

Our experienced and dedicated global program managers have the knowledge necessary to provide clients with a proactive, timely, and seamless approach to position your molecule for greater therapeutic and financial success. We provide a global network integrated by program managers to deliver coordination, commitment, and accountability across the entire supply chain. Our managers currently oversee and manage 40 programs as of 2019 and have 24+ years of combined drug development experience. They are the human connector that integrates the sites and capabilities into a single network, by having:

Tailored solutions just for you

Whether your goal is out-licensing at Phase IIb or taking your molecule to full commercialization, it requires a dedicated, trusted and experienced partner that understands your complex needs. Our team of global experts provide unified program management, scientific and technical insight, and reduce redundancies to ensure success in your drug development journey. By partnering with us, you’re able to create and customize your own flexible integrated offering based on your specific needs, all while working alongside our team of experts to find a solution tailored just for you. We are patient-centric focused and offer customizable solutions that include:

Delivering global excellence

Thermo Fisher Scientific is your global partner of choice for an integrated solution to streamline your drug development program. We understand the complex journey ahead and are experienced in working with new and emerging clients. In 2019, 74 percent of our new business in product development was with new and emerging clients—238 drug development projects in 2019 alone, including 96 Phase I projects, 72 Phase II projects, and 70 Phase III projects. As an industry-leading partner with a proven track record, we have outsourced 109 NDA approvals in the last decade—that’s more than three times the number of the next-ranking CDMO.

Our integrated network of technical, quality, and customer engagement teams are ready to support your drug development journey. The Pharma Services network has 55+ sites across five continents and employs approximately 3,500 scientists, technicians, and engineers with deep technical expertise all working together to ensure the success of your molecule. We currently offer manufacturing locations in the United States, Europe, and Australia, which provides you with simplified logistics and R&D tax advantages. We offer a broad range of solutions that include:

Benefits of partnering with us

Thermo Fisher Scientific is your global partner of choice for an integrated solution to streamline your drug development program. We understand the complex journey ahead and are experienced in working with new and emerging clients. In 2019, 74 percent of our new business in product development was with new and emerging clients—238 drug development projects in 2019 alone, including 96 Phase I projects, 72 Phase II projects, and 70 Phase III projects. As an industry-leading partner with a proven track record, we have outsourced 109 NDA approvals in the last decade—that’s more than three times the number of the next-ranking CDMO.

With our breadth of experience, vast access to scientific experts, and a global integrated network, we can provide you with a customizable solution that works to reduce your development timeline. We apply a science-driven, risk-based approach to every step of the development and manufacturing process, while providing you with a global footprint and the scientific and therapeutic expertise to ensure your discovery makes it to the patients who need it most. We have one shared commitment—your drug development success.

  1. Olivier J. Wouters, PhD; Martin McKee, MD, DSc; Jeroen Luyten, PhD. “Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018”. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166
  2. Novel Drug Therapy Approvals Annual Reports, 2015 to 2019

Download our Quick to Care™ program fact sheet to learn more.

Additional Resources